KW-0761
Phase 2Completed 0 watching 0 views this week⚡ Active
52
Development Stage
✓
Pre-clinical✓
Phase 13
Phase 24
Phase 35
ApprovedIndication / Disease
Adult T-cell Leukemia-lymphoma
Conditions
Adult T-cell Leukemia-lymphoma
Trial Timeline
Jun 1, 2009 → Nov 1, 2010
NCT ID
NCT00920790About KW-0761
KW-0761 is a phase 2 stage product being developed by Kyowa Kirin for Adult T-cell Leukemia-lymphoma. The current trial status is completed. This product is registered under clinical trial identifier NCT00920790. Target conditions include Adult T-cell Leukemia-lymphoma.
Hype Score Breakdown
Clinical
17
Activity
12
Company
10
Novelty
5
Community
5
Clinical Trials (5)
| NCT ID | Phase | Status |
|---|---|---|
| NCT01192984 | Phase 2 | Completed |
| NCT01226472 | Phase 2 | Completed |
| NCT00920790 | Phase 2 | Completed |
| NCT00888927 | Phase 1/2 | Completed |
| NCT00355472 | Phase 1 | Completed |
Competing Products
20 competing products in Adult T-cell Leukemia-lymphoma
| Product | Company | Stage | Hype Score |
|---|---|---|---|
| BBP-398 + sotorasib | BridgeBio Pharma | Phase 1 | 30 |
| Daridorexant + Placebo | Idorsia | Phase 1 | 28 |
| SON-1010 (IL12-FHAB) | Sonnet BioTherapeutics | Phase 1 | 28 |
| Somatropin | Eli Lilly | Phase 3 | 77 |
| agenT-797 | MiNK Therapeutics | Phase 1 | 25 |
| Pegilodecakin | Eli Lilly | Phase 1 | 33 |
| eFT226 + Sotorasib + Fulvestrant + Abemaciclib + Trastuzumab | eFFECTOR Therapeutics | Phase 1/2 | 33 |
| Lazertinib(G001) + Lazertinib(G002) | Yuhan | Phase 1 | 33 |
| Patritumab deruxtecan | Daiichi Sankyo | Phase 2 | 52 |
| DJ-927 + capecitabine | Daiichi Sankyo | Phase 1 | 33 |
| Valemetostat Tosylate | Daiichi Sankyo | Phase 2 | 52 |
| Roxadustat | Astellas Pharma | Phase 1 | 33 |
| ASP3325 + Placebo | Astellas Pharma | Phase 1 | 33 |
| TRK-100STP | Astellas Pharma | Phase 1 | 33 |
| Ensitrelvir | Shionogi | Phase 1 | 33 |
| E6130 + Placebo | Eisai | Phase 1 | 33 |
| E7389 + E7389 + E7389 | Eisai | Phase 1 | 33 |
| Eribulin Mesylate | Eisai | Phase 1 | 33 |
| E2022 + E2022 + E2022 + E2022 + E2022 | Eisai | Phase 1 | 33 |
| Donepezil Hydrochloride + Donepezil Hydrochloride + Donepezil Hydrochloride + Donepezil Hydrochloride | Eisai | Phase 1 | 33 |